Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 2.67 is 65% below its 5-year average of 7.57, near the low end of its 5-year range (2.38–32.03).
As of the fiscal period ended Tuesday, June 30, 2026. 7.42% below its 12-month average of 2.89.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.67.
QUICK RATIO (ACID-TEST)
2.67
QUICK RATIO (ACID-TEST) AVG TTM
2.89
QUICK RATIO (ACID-TEST) AVG 3Y
4.87
QUICK RATIO (ACID-TEST) AVG 5Y
7.57
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-7.42%
CURRENT VS 3Y AVG
-45.07%
CURRENT VS 5Y AVG
-64.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.33
median of 858 covered companies
CURRENT VS SECTOR MEDIAN
-19.81%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.03B
Quick Ratio (Acid-Test)
2.67
TTM Avg
2.89
3Y Avg
4.87
5Y Avg
7.57
Market Cap
$2.99B
Quick Ratio (Acid-Test)
64.07
TTM Avg
24.32
3Y Avg
16.73
5Y Avg
16.77
Market Cap
$3.08B
Quick Ratio (Acid-Test)
12.12
TTM Avg
10.47
3Y Avg
8.53
5Y Avg
7.00
Market Cap
$3.09B
Quick Ratio (Acid-Test)
8.32
TTM Avg
8.81
3Y Avg
8.76
5Y Avg
9.71
Market Cap
$3.19B
Quick Ratio (Acid-Test)
3.17
TTM Avg
4.10
3Y Avg
7.42
5Y Avg
12.78
Market Cap
$2.84B
Quick Ratio (Acid-Test)
12.02
TTM Avg
18.93
3Y Avg
12.46
5Y Avg
15.83
Market Cap
$2.80B
Quick Ratio (Acid-Test)
6.07
TTM Avg
7.05
3Y Avg
8.10
5Y Avg
8.04
Market Cap
$3.33B
Quick Ratio (Acid-Test)
17.91
TTM Avg
1.68
3Y Avg
1.68
5Y Avg
1.68
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.03B | 2.67 | 2.89 | 4.87 | 7.57 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.99B | 64.07 | 24.32 | 16.73 | 16.77 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | 12.12 | 10.47 | 8.53 | 7.00 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.09B | 8.32 | 8.81 | 8.76 | 9.71 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 3.17 | 4.10 | 7.42 | 12.78 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.84B | 12.02 | 18.93 | 12.46 | 15.83 |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 6.07 | 7.05 | 8.10 | 8.04 |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 3.19 | 2.81 | 2.79 | 3.25 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | 17.91 | 1.68 | 1.68 | 1.68 |
| Precigen, Inc. (PGEN)vs › | $2.72B | 3.89 | 3.79 | 3.02 | 3.31 |
Quick Ratio
2.67
Excludes inventory
Current Ratio
2.92
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 2.67 |
| 2026-03-31 | 2.46 |
| 2025-12-31 | 2.99 |
| 2025-09-30 | 3.28 |
| 2025-06-30 | 3.04 |
| 2025-03-31 | 3.37 |
| 2024-12-31 | 3.97 |
| 2024-09-30 | 2.38 |
| 2024-06-30 | 8.19 |
| 2024-03-31 | 9.61 |
| 2023-12-31 | 6.80 |
| 2023-09-30 | 6.39 |
| 2023-06-30 | 8.14 |
| 2023-03-31 | 9.70 |
| 2022-12-31 | 11.37 |
| 2022-09-30 | 13.27 |
| 2022-06-30 | 10.75 |
| 2022-03-31 | 10.89 |
| 2021-12-31 | 12.09 |
| 2021-09-30 | 20.03 |
| 2021-06-30 | 32.03 |
| 2021-03-31 | 30.37 |
| 2020-12-31 | 12.96 |
| 2020-09-30 | 9.18 |
| 2020-06-30 | 11.83 |
| 2020-03-31 | 20.77 |
| 2019-12-31 | 20.33 |
| 2019-09-30 | 3.23 |
| 2019-06-30 | 9.02 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 19.12 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
